Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $4.71B | +5.2% | $-311.0M | $-1.11 | -203.7% | 45.7% | 13.3% |
| Q4 2025 Dec 2025 | $5.25B | — | $382.0M | $1.34 | +28.8% | 45.9% | 12.6% |
| Q3 2025 Sep 2025 | $5.89B | — | $493.0M | — | — | 47.5% | 14.0% |
| Q2 2025 Jun 2025 | $5.51B | — | $574.0M | $2.00 | — | 47.8% | 17.8% |
| Q1 2025 Mar 2025 | $4.48B | — | $308.0M | $1.07 | — | 41.5% | 10.7% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
With Becton, Dickinson and Company shares sliding, is this elite Dividend King offering a rare bargain or a warning sign for investors?